AstraZeneca scraps Phase 3 trial of bispecific volrustomig in lung cancer after interim data miss
AstraZeneca discontinued a late-stage trial of volrustomig in metastatic non-small cell lung cancer after an interim check showed survival goals were unlikely t
BioPharma Dive · +4 outlets
EyePoint shares plunge after Phase 3 miss for wet AMD drug-device combo Duravyu
EyePoint's experimental treatment for wet age-related macular degeneration failed to maintain vision with less frequent injections versus standard care in a piv
BioPharma Dive · +6 outlets
Argenx shares jump on Phase 3 data for Vyvgart in new autoimmune indication
Positive Phase 3 results for Vyvgart in immune-mediated necrotizing myopathy (IMNM) give investors confidence in approval for a condition with no approved treat
BioPharma Dive · +14 outlets
Summit and Akeso's lung cancer drug ivonescimab shows worsening tumor-progression benefit
Fresh data from Summit and Akeso revealed that the survival benefit of their China-approved lung cancer drug ivonescimab is degrading over time.
STAT · +3 outlets
FDA approves Zenbexus (iberdomide), a new class of multiple myeloma drug for relapsed patients
The FDA cleared iberdomide (Zenbexus) for patients with multiple myeloma whose cancer returned after earlier treatment, offering a new option for rural and frai
Medical Daily · +14 outlets
Regeneron ends eye disease trial for anti-CD3 antibody following safety review
Regeneron discontinued a clinical trial for an anti-CD3 antibody in an eye disease after a safety review.
Fierce Biotech · +1 outlets
Sandoz to license three biosimilar drug rights from Shanghai Henlius Biotech for up to $77M
Sandoz will pay up to $77 million for rights to three biosimilar drugs from Shanghai Henlius Biotech, expanding its biosimilar pipeline.
Investing.com South Africa · +14 outlets
Slate and Fulcrum to combine in reverse merger with $245M financing for migraine trials
Slate will use a reverse merger with Fulcrum to list on Nasdaq and raise $245 million to fund migraine clinical trials.
BioPharma Dive · +5 outlets
Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
Evaxion is discontinuing its solid tumor vaccine program to concentrate resources on a brain cancer candidate developed with Duke University.
Fierce Biotech
Sanofi to lay off 229 workers in Massachusetts a year after Blueprint Medicines acquisition
Sanofi will cut more than 200 jobs in Massachusetts, a year after its $9.1 billion acquisition of Blueprint Medicines.
STAT · +7 outlets
New mutation cluster tied to malaria drug resistance found in Uganda
Researchers identified a new cluster of mutations associated with drug resistance in malaria parasites in Uganda.
Drug Discovery News · +3 outlets
AbelZeta receives FDA IND clearance for bispecific CAR-T C-CAR039 in large B-cell lymphoma
The FDA cleared AbelZeta's investigational new drug application for a bispecific CAR-T therapy targeting large B-cell lymphoma.
BioPharma APAC · +4 outlets
Enhertu becomes first HER2-directed therapy to beat chemoimmunotherapy in first-line lung cancer
Enhertu (trastuzumab deruxtecan) showed superior efficacy versus chemoimmunotherapy as a first-line treatment in HER2-mutant lung cancer.
AllSci · +8 outlets
Kelun-Biotech reports H1 2026 results with commercialization revenue up 112%
Kelun-Biotech's first-half 2026 revenue surged 112% to RMB 657 million, driven by commercial-stage product sales.
Investing.com Australia · +4 outlets
FDA grants accelerated approval to new melanoma drug based on herpes virus
The FDA approved a novel oncolytic virus therapy derived from herpes simplex virus for the treatment of melanoma.
optometryadvisor.com · +14 outlets
FDA approves autoinjector of lerodalcibep-liga with updated indication
The FDA approved an autoinjector formulation of lerodalcibep-liga, a lipid-lowering therapy, with an updated indication.
Drug Topics · +10 outlets
PTC Therapeutics targets Fabry gene therapy in $111M bankruptcy auction deal
PTC Therapeutics is pursuing the acquisition of a Fabry disease gene therapy program through a $111 million bankruptcy auction.
TradingView · +3 outlets
AbCellera stock soars 64% following positive menopause drug trial
AbCellera shares surged after positive clinical trial results for a menopause drug candidate.
sekbernews.id